IL143023A0 - Hiv replication inhibiting pyrimidines - Google Patents

Hiv replication inhibiting pyrimidines

Info

Publication number
IL143023A0
IL143023A0 IL14302399A IL14302399A IL143023A0 IL 143023 A0 IL143023 A0 IL 143023A0 IL 14302399 A IL14302399 A IL 14302399A IL 14302399 A IL14302399 A IL 14302399A IL 143023 A0 IL143023 A0 IL 143023A0
Authority
IL
Israel
Prior art keywords
hiv replication
replication inhibiting
inhibiting pyrimidines
pyrimidines
hiv
Prior art date
Application number
IL14302399A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143023(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL143023A0 publication Critical patent/IL143023A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
IL14302399A 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines IL143023A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (1)

Publication Number Publication Date
IL143023A0 true IL143023A0 (en) 2002-04-21

Family

ID=26805159

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14302399A IL143023A0 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines
IL169949A IL169949A (en) 1998-11-10 2005-07-28 History of pyrimidines, their preparation, pharmaceutical preparations containing them and their use in HIV treatment drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL169949A IL169949A (en) 1998-11-10 2005-07-28 History of pyrimidines, their preparation, pharmaceutical preparations containing them and their use in HIV treatment drugs

Country Status (41)

Country Link
US (5) US6878717B2 (hu)
EP (2) EP1002795B1 (hu)
JP (1) JP3635238B2 (hu)
KR (1) KR100658489B1 (hu)
CN (1) CN1214013C (hu)
AP (1) AP1683A (hu)
AR (1) AR024227A1 (hu)
AT (2) ATE455107T1 (hu)
AU (2) AU762523C (hu)
BG (1) BG65103B1 (hu)
BR (1) BRPI9915552B8 (hu)
CA (1) CA2350801C (hu)
CY (1) CY2008021I2 (hu)
CZ (1) CZ301367B6 (hu)
DE (3) DE69905683T2 (hu)
DK (1) DK1002795T3 (hu)
EA (1) EA004049B1 (hu)
EE (1) EE05086B1 (hu)
ES (2) ES2193664T3 (hu)
FR (1) FR09C0004I2 (hu)
HK (2) HK1025330A1 (hu)
HR (2) HRP20010161B9 (hu)
HU (2) HU230394B1 (hu)
ID (1) ID28376A (hu)
IL (2) IL143023A0 (hu)
LT (1) LTC1002795I2 (hu)
LU (1) LU91528I2 (hu)
MY (1) MY121108A (hu)
NL (1) NL300373I2 (hu)
NO (3) NO318801B1 (hu)
NZ (1) NZ511116A (hu)
OA (1) OA11674A (hu)
PL (1) PL204427B1 (hu)
PT (1) PT1002795E (hu)
SI (1) SI1002795T1 (hu)
SK (2) SK287269B6 (hu)
TR (1) TR200101306T2 (hu)
TW (1) TWI238161B (hu)
UA (1) UA70966C2 (hu)
WO (1) WO2000027825A1 (hu)
ZA (1) ZA200103769B (hu)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
ES2542326T3 (es) * 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
EP1337931A4 (en) * 2000-11-01 2005-05-11 Snapnames Com Inc DOMAIN NAME ACQUISITION AND MANAGEMENT SYSTEM AND METHOD
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
EP2090571B1 (de) * 2001-10-17 2012-05-16 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US7183288B2 (en) 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
EP1448556A1 (en) 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003093344A1 (en) * 2002-05-03 2003-11-13 Janssen Pharmaceutica N.V. Polymeric microemulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN101481356B (zh) * 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
MXPA05008368A (es) * 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
WO2005011702A1 (en) * 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
RU2401833C2 (ru) 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
TW200626574A (en) * 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
CN101027288B (zh) * 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
BRPI0515935B8 (pt) 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
CA2583187A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
AU2006208778B2 (en) 2005-01-27 2012-08-09 Janssen Sciences Ireland Uc HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
JP5247154B2 (ja) * 2005-02-18 2013-07-24 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性２−（４−シアノフェニルアミノ）ピリミジンオキシド誘導体
RU2401261C2 (ru) * 2005-03-04 2010-10-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MX2007014881A (es) * 2005-05-26 2008-02-15 Tibotec Pharm Ltd Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7754773B2 (en) * 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007206950B2 (en) 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
DK1981874T3 (da) 2006-01-19 2009-09-28 Janssen Pharmactuica N V Aminophenylderivater som nye inhibitorer af histondeacetylase
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
EP2004641B1 (en) 2006-03-30 2010-09-29 Tibotec Pharmaceuticals Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
WO2007141308A1 (en) * 2006-06-06 2007-12-13 Tibotec Pharmaceuticals Ltd. Process for preparing spray dried formulations of tmc125
CN101677963B (zh) 2006-06-19 2012-05-30 奥尔制药公司 药物组合物
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
EP2104491B1 (en) 2006-12-06 2017-02-22 Janssen Sciences Ireland UC Hydrobromide salt of an anti-hiv compound
AU2007341228B2 (en) 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
CA2674178C (en) 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CN102369009B (zh) 2009-03-30 2014-04-30 泰博特克药品公司 依曲韦林和烟酰胺的共晶体
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
EP2342186B1 (en) 2009-06-22 2014-09-17 Emcure Pharmaceuticals Limited Process for synthesis of etravirine
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
WO2012001695A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etra virine intermediate and polymorphs of etravirine
KR20130099040A (ko) 2010-08-10 2013-09-05 셀진 아빌로믹스 리서치, 인코포레이티드 Ｂｔｋ 억제제의 베실레이트 염
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
BR112013010564B1 (pt) 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
HUE046617T2 (hu) 2010-11-10 2020-03-30 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
PL2702045T3 (pl) 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
ES2690971T3 (es) 2011-08-23 2018-11-23 Asana Biosciences, Llc Compuestos pirimido-piridazinona y uso de los mismos
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
EP2825042B1 (en) 2012-03-15 2018-08-01 Celgene CAR LLC Salts of an epidermal growth factor receptor kinase inhibitor
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015007945A (es) 2012-12-21 2016-02-16 Verlyx Pharma Inc Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
ES2929526T3 (es) 2015-06-22 2022-11-29 Arena Pharm Inc Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
DE68918804T2 (de) 1988-03-31 1995-02-23 Mitsubishi Chem Ind Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten.
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Ges Innenhochdruckverfahren Achsschwinge
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
WO1999050250A1 (en) * 1998-03-27 1999-10-07 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidine derivatives
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
US8530655B2 (en) 2013-09-10
AU762523C (en) 2004-02-12
AR024227A1 (es) 2002-09-25
EA200100536A1 (ru) 2002-02-28
AP1683A (en) 2006-11-29
US7037917B2 (en) 2006-05-02
HRP20080359A2 (en) 2008-12-31
FR09C0004I2 (fr) 2010-06-11
SI1002795T1 (en) 2003-10-31
LU91528I2 (fr) 2009-04-20
UA70966C2 (uk) 2004-11-15
PL204427B1 (pl) 2010-01-29
ATE233740T1 (de) 2003-03-15
BG65103B1 (bg) 2007-02-28
NZ511116A (en) 2003-08-29
ATE455107T1 (de) 2010-01-15
HK1048817B (zh) 2010-04-09
IL169949A (en) 2011-02-28
KR20010075235A (ko) 2001-08-09
US20040039005A1 (en) 2004-02-26
SK287269B6 (sk) 2010-05-07
NO318801B1 (no) 2005-05-09
EP1270560A1 (en) 2003-01-02
TWI238161B (en) 2005-08-21
HU227453B1 (en) 2011-06-28
CY2008021I1 (el) 2010-07-28
KR100658489B1 (ko) 2006-12-18
AU2011200708A1 (en) 2011-03-10
TR200101306T2 (tr) 2001-10-22
ID28376A (id) 2001-05-17
US8003789B2 (en) 2011-08-23
LU91528I9 (hu) 2019-01-02
WO2000027825A1 (en) 2000-05-18
NO2021015I1 (no) 2021-03-29
NO20011696D0 (no) 2001-04-04
US6878717B2 (en) 2005-04-12
NO20011696L (no) 2001-04-04
NO2009003I1 (no) 2009-03-09
NO2009003I2 (no) 2010-06-07
US20080176880A1 (en) 2008-07-24
BRPI9915552B8 (pt) 2021-05-25
CZ20011533A3 (cs) 2001-10-17
OA11674A (en) 2005-01-12
CA2350801C (en) 2008-05-20
MY121108A (en) 2005-12-30
SK6032001A3 (en) 2002-01-07
BR9915552B1 (pt) 2013-11-19
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
LTPA2008016I1 (lt) 2021-04-26
US20050288278A1 (en) 2005-12-29
EP1002795B1 (en) 2003-03-05
ES2193664T3 (es) 2003-11-01
US20110263625A1 (en) 2011-10-27
EP1002795A1 (en) 2000-05-24
LTC1002795I2 (lt) 2021-06-10
BG105418A (en) 2001-11-30
HUP0104177A3 (en) 2003-01-28
HRP20010161A2 (en) 2002-02-28
HRP20010161B9 (hr) 2014-10-24
ES2338760T3 (es) 2010-05-12
EE200100252A (et) 2002-10-15
FR09C0004I1 (hu) 2009-02-27
PL347586A1 (en) 2002-04-08
EE05086B1 (et) 2008-10-15
DE69905683T2 (de) 2004-03-18
NL300373I1 (nl) 2009-03-02
CN1214013C (zh) 2005-08-10
CY2008021I2 (el) 2010-07-28
CN1322198A (zh) 2001-11-14
HK1025330A1 (en) 2000-11-10
CA2350801A1 (en) 2000-05-18
EA004049B1 (ru) 2003-12-25
HRP20010161B1 (en) 2009-03-31
HUP0104177A2 (hu) 2002-03-28
DE122009000003I1 (de) 2009-05-20
AU762523B2 (en) 2003-06-26
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
HK1048817A1 (en) 2003-04-17
NL300373I2 (nl) 2009-04-01
JP3635238B2 (ja) 2005-04-06
EP1270560B1 (en) 2010-01-13
BR9915552A (pt) 2001-08-14
CZ301367B6 (cs) 2010-02-03
HU230394B1 (hu) 2016-04-28
PT1002795E (pt) 2003-07-31
AU6200899A (en) 2000-05-29
ZA200103769B (en) 2002-08-12
JP2002529456A (ja) 2002-09-10
HRP20080359B1 (hr) 2016-01-01
DE69941934D1 (de) 2010-03-04

Similar Documents

Publication Publication Date Title
HK1025330A1 (en) Hiv replication inhibiting pyrimidines
IL138669A0 (en) Hiv inhibiting pyrimidine derivatives
EG24684A (en) HIV replication inhibiting pyrimidines
DE59902573D1 (en) Dihydropyrimidine
HK1054940A1 (en) Pyrimidine derivatives
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
HK1078079A1 (en) Pyrimidine derivatives
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
MXPA03000504A (es) Derivados de pirimidina.
DE69940886D1 (en) Hiv impfstoff
IL166937A (en) Uracil compounds
ZA200007155B (en) Uracil compounds and use thereof.
ZA200100906B (en) Uracil compounds and use thereof.
EP0954316A4 (en) PYRIMIDINE DERIVATIVES
GB9810027D0 (en) Incinerator
SI1303496T1 (sl) Pirimidinski derivati

Legal Events

Date Code Title Description
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
EXTJ Intention to grant a patent extension

Free format text: PRODUCT NAME: ETRAVIRINE

Extension date: 20201101

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: ETRAVIRINE

Extension date: 20201101

EXTG Extension of patent term granted

Extension date: 20201101

KB Patent renewed